Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters
- Qingjian Wanga,
- Yinjin Wanga,
- Dallas M Hydeb,
- Philip J Gotwalsc,
- Victor E Kotelianskyc,
- Sarah T Ryanc,
- Shri N Giria
- aDepartment of Molecular Biosciences, bDepartment of Anatomy, Physiology, and Cell Biology, cSchool of Veterinary Medicine, University of California, Davis, California 95616, USA Biogen Inc, Cambridge, Massachusetts 02142, USA
- Dr S N Giri.
- Received 1 February 1999
- Revision requested 29 March 1999
- Revised 4 May 1999
- Accepted 21 May 1999
BACKGROUND Transforming growth factor β (TGF-β) is a key mediator of collagen synthesis in the development of lung fibrosis. It has previously been shown that the administration of TGF-β antibody and TGF-β binding proteoglycan, decorin, reduced bleomycin (BL) induced lung fibrosis in animals. The present study was carried out to investigate whether intratracheal instillation of TGF-β soluble receptor (TR) would minimise the BL induced lung fibrosis in hamsters.
METHODS The effect of a recombinant TR (TGFβRII) on the lung collagen accumulation was evaluated in a BL hamster model of pulmonary fibrosis. Animals were divided into four groups and intratracheally injected with saline or BL at 6.5 U/4 ml/kg followed by intratracheal instillation of phosphate buffered saline (PBS) or 4 nmol TR in 0.3 ml twice a week. Twenty days after the first intratracheal instillation the hamsters were killed for bronchoalveolar lavage (BAL) fluid, biochemical, and histopathological analyses.
RESULTS Treatment of hamsters with TR after intratracheal instillation of BL significantly reduced BL induced lung fibrosis as shown by decreases in the lung hydroxyproline level and prolyl hydroxylase activity, although they were still significantly higher than those of the saline control. Histopathological examination showed a considerable decrease in BL induced fibrotic lesions by TR treatment. However, TR did not prevent the BL induced increases in total cells and protein in the BAL fluid.
CONCLUSIONS These results suggest that TR has antifibrotic potential in vivo and may be useful in the treatment of fibrotic diseases where increased TGF-β is associated with excess collagen accumulation.
Interstitial pulmonary fibrosis (IPF) is a crippling disease that leads to a reduction of lung compliance and impairment of the vital gas exchange function due to an excess accumulation of collagen in the interstitium resulting from inflammatory and fibroproliferative changes of the lung.1 IPF may result from a wide range of processes including the use of bleomycin (BL) in chemotherapy. The pneumotoxic effect of BL has been used to generate reproducible pulmonary fibrosis in animals.2 Intratracheal instillation of BL in hamsters has been shown to cause lung fibrosis similar to that seen in humans and therefore this model has been widely used for studying mechanisms of fibrogenesis and for screening potentially desirable antifibrotic compounds.3-5
The mechanisms of BL induced pulmonary injury and the subsequent development of fibrosis are not completely understood. BL is known to generate reactive oxygen species upon binding to DNA and iron which cause DNA damage.6 The interaction of BL with DNA appears to initiate the inflammatory and fibroproliferative changes via a concerted action of various cytokines, leading to accumulation of collagen in the lung. One of the most important mediators of collagen synthesis is transforming growth factor β (TGF-β) which is known to stimulate collagen production.7 8 While TGF-β1, TGF-β2, and TGF-β3all exert profibrotic effects in vitro, TGF-β1 appears to be the predominant isoform expressed during experimental pulmonary fibrosis.9 TGF-β stimulates procollagen gene transcription, increases mRNA stability, and decreases intracellular degradation of procollagen.10-12 In animal models of pulmonary fibrosis the levels of TGF-β mRNA and protein were increased.13-15 Immunohistochemical staining of the lung after instillation of BL showed a patchy localisation of TGF-β initially in the subepithelial matrix followed by intense staining of macrophages, and later intense staining was observed at the edges of areas of repair with hypercellularity and collagen deposition.16 Furthermore, TGF-β antagonists in the form of neutralising antibody or the TGF-β binding proteoglycan, decorin, reduced BL induced lung fibrosis.17 18
In mammalian cells the response to TGF-β is mediated by type I and type II cell surface receptors with cytoplasmic serine/threonine kinase domains.19 20 The type II signalling receptors (TRIIs) are specific for their respective ligands and promote ligand specific function.21 TRII is a constitutively active kinase which is recognised by TRI only after ligand binding to TRII and, subsequently, TRI is recruited into the complex and phosphorylated by TRII.22 TGF-β binds directly to TRII, allowing this receptor to associate with and phosphorylate TRI which then propagates the signal.23 In this respect, a soluble version of the TGF-β receptor may prevent the interaction of TGF-β with the cell surface receptor, thereby neutralising TGF-β activity.24 25 Indeed, it has been shown that the soluble extracellular domain of TRII is able to neutralise the inhibitory activity of TGF-β on cell proliferation in vitro.26 In searching for TGF-β antagonists we have generated a chimeric TGF-β soluble receptor that has high affinity for TGF-β but lacks the ability to initiate signal transduction events necessary for function. In this paper we show that the TGF-β soluble receptor has antifibrotic potential in animals.
Pathogen free male Golden Syrian hamsters weighing 120–130 g were purchased from Simonsen Inc (Gilroy, California, USA); bleomycin sulfate (Blenoxane) was a gift from Bristol Laboratories (Syracuse, New York, USA); TGF-β soluble receptor as TGFβRII was produced as described below at Biogen Inc (Cambridge, Massachusetts, USA); TGF-β1 was purchased from R&D Systems (Minneapolis, Minnesota, USA); l-(3,4-3H)proline for labelling the procollagen substrate of prolyl hydroxylase was obtained from NEN Life Science Products (Boston, Massachusetts, USA); Z-fix, an aqueous buffered zinc formalin, was purchased from Anatech Ltd (Battle Creek, Michigan, USA). All other reagents were of reagent grade or higher purity and obtained from standard commercial sources.
PRODUCTION OF TGF-β SOLUBLE RECEPTOR TGFβR:FC
The recombinant rabbit TGFβR:Fc fusion gene (pTGFβR:Fc), comprised of the extracellular domain of the rabbit type II TGF-β receptor fused to the Fc portion of human IgG1, was constructed as follows. The extracellular domain of the rabbit type II TGF-β receptor was amplified from clone MIS-3f1127 by conventional polymerase chain reaction (PCR). Amplified sequences were flanked with a 5′ NotI and 3′SalI restriction site and subsequently digested with these restriction enzymes. The human IgG1 H chain C region containing the hinge region, the CH2, and CH3 sequences were isolated with H chain specific primers by PCR amplification as previously described.28 Amplified sequences were flanked by a 5′ SalI and a 3′NotI restriction enzyme recognition site and subsequently digested with these restriction enzymes. The receptor and IgG DNA fragments were cloned into the NotI restriction enzyme site in plasmid SAB13228 and transformed into competent bacteria. Plasmids recovered from the transformants were analysed for the correct orientation of assembled fragments and the entire coding sequence was confirmed by DNA sequencing.
The recombinant rabbit TGFβR:Fc fusion gene was transfected into Chinese hamster ovary (CHO) cells. After the initial transfection cells were selected in 250 nM methotrexate. The resulting colonies were expanded and analysed for TGFβR:Fc fusion gene expression. Clones expressing the highest levels of TGFβR:Fc were selected for production of the fusion protein. TGFβR:Fc, which is dimeric, was purified from culture supernatant by protein A-Sepharose affinity chromatography under sterile and endotoxin free conditions.
MINK LUNG EPITHELIAL CELL PROLIFERATION ASSAY
Mink lung (Mv1Lu) cells were maintained in MEM supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum. To test, serial dilutions of TGFβR:Fc or control (monomeric TGF-β receptor type II extracellular domain; R&D Systems) were incubated with 0.1 ng/ml TGF-β1 for one hour in assay medium in a 96-well microtitre tissue culture plate. Mv1Lu cells were resuspended and added to the assay plate at a concentration of 4000 cells per well. The cells were incubated at 37°C for 72 hours and pulsed with [3H]thymidine (Amersham; 70–86 Ci/mmol) for an additional four hours. DNA synthesis, which reflects cell proliferation, was determined by measuring incorporation of [3H]thymidine.
TREATMENT OF ANIMALS
Hamsters were housed in groups of four in facilities approved by the American Association for the Accreditation of Laboratory Animal Care. All care was in accordance with the National Institute of Health guidelines for animal welfare. The hamsters were allowed to acclimatise in the facilities for one week before all treatments. A 12 hour/12 hour light/dark cycle was maintained and the hamsters had access to water and Rodent Laboratory Chow 5001 (Purina Mills Inc, St Louis, Missouri, USA) ad libitum. The animals were randomly divided into four experimental groups: (1) SA + PBS; (2) SA + TR; (3) BL + PBS; and (4) BL + TR. They were intratracheally injected with a single dose of SA or BL at 6.5 U/4ml/kg under pentobarbital anaesthesia. Starting two days later, the hamsters received intratracheal instillation of PBS or 4 nmol TR in 0.3 ml twice a week. Twenty days after the BL instillation they were killed under pentobarbital anaesthesia for bronchoalveolar lavage (BAL) fluid, biochemical, and histopathological analyses.
PREPARATION OF BAL FLUID AND LUNG TISSUE
After anaesthesia the abdominal cavity was opened and the descending abdominal aorta exsanguinated. The lungs were prepared for lavage by cannulating the trachea with Teflon tubing attached to a syringe. The lung lavage was carried out with 12 ml of cold isotonic SA delivered in 3 ml aliquots. An aliquot of the BAL fluid was portioned for total and differential cell counting. The remaining BAL fluid was centrifuged at 1500g for 20 minutes at 4°C and the resulting supernatant aliquoted and stored at –70°C. After bronchoalveolar lavage the thoracic cavity was opened and the lung lobes were quickly dissected free of non-parenchymal tissue, immediately frozen in liquid nitrogen, and stored at –70°C. The frozen lungs were later thawed and homogenised in 0.1 M KCl, 0.02 M Tris (pH 7.6) with a Polytron homogeniser (Brinkmann Instruments Inc, Westbury, New York, USA). The homogenate was thoroughly mixed by repeated inversions and the final homogenate volumes (9–10 ml) were recorded. The homogenate was divided into several aliquots and stored at –70°C for biochemical measurements.
DETERMINATION OF HYDROXYPROLINE
For lung hydroxyproline assay 1 ml of homogenate was precipitated with 0.25 ml ice cold 50% (w/v) trichloroacetic acid, centrifuged, and the precipitate hydrolysed in 2 ml of 6 N HCl for 18 hours at 110°C. The hydroxyproline content was measured by the technique described by Woessner.29
DETERMINATION OF PROLYL HYDROXYLASE (EC 220.127.116.11) ACTIVITY
The preparation of prolyl hydroxylase substrate (procollagen) and the method for prolyl hydroxylase assay are described in our previous paper.30 Briefly, tibias freshly isolated from 10 day old chicken embryos were labelled with [3H]-proline in culture medium at 37°C for six hours. After removing the unincorporated label by washing, the tissue was homogenated and centrifuged at 3000g for 20 minutes at 4°C. The resulting supernatant was dialysed extensively to remove the unincorporated label. The labelled procollagen substrate was aliquoted and stored at –70°C. The incubation mixture for the enzyme assay in a total volume of 2 ml consisted of ferrous ammonium sulphate (0.1 mmol/l), α-ketoglutaric acid (0.1 mmol/l), [3H]-proline procollagen (200 000 dpm), lung homogenate (0.2 ml), ascorbic acid (0.5 mmol/l), and Tris-HCl buffer (0.1 mol/l, pH 7.8). The reaction was started by the addition of ascorbic acid and stopped by adding 0.2 ml of 50% trichloroacetic acid after 30 minutes at 37°C in a Dubnoff metabolic shaker. During the reaction tritiated water is released in stoichiometric proportion to prolyl hydroxylation and it is used as a measure of the enzyme activity. The tritiated water of the reaction system was separated by vacuum distillation of the whole reaction mixture and counted for radioactivity. The enzyme activity was expressed as dpm3H2O released per total lung per 30 minutes.
DETERMINATION OF CELL COUNTS IN BAL FLUID
The total and differential cell numbers in the BAL fluid were determined as previously described.5 Briefly, total leucocyte numbers in the BAL fluid were estimated by Coulter counter (Model F, Coulter Electronics Inc, Hialeah, Florida, USA) according to the user’s manual. Slides for differential cell counts were prepared on a Shandon cytospin using 100 μl lavage fluid and stained with Diff-Quik (American Scientific, McGaw Park, Illinois, USA). Differential cell counts were performed on a Zeiss microscope at ×630. Macrophages, neutrophils, and lymphocytes were counted based on 400 cells per slide.
BAL FLUID PROTEIN ASSAY
Protein content in the BAL fluid supernatant was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, California, USA) and bovine serum albumin was used as the standard.
Three animals from each of the SA + PBS and SA + TR groups and four animals from each of the BL + PBS and BL + TR groups were randomly chosen for histopathological evaluation at the end of the experiment. The abdominal cavity of the animal was opened and the descending abdominal aorta exsanguinated. Immediately thereafter the lung tissue was prepared for histological analysis as described elsewhere.5 Briefly, after cannulating the trachea with a blunt needle the thoracic cavity was opened and both the heart and lung were removed en bloc. The lungs were fixed with Z-fix solution via the trachea at a pressure of 30 cm H2O. Before embedding the lung tissue the heart and all non-pulmonary tissue were isolated by blunt dissection and removed. The right cranial and caudal lobes and the left lobe were later blocked, embedded in paraffin, cut in 7 μm sections, and stained with haematoxylin and eosin. The lung parenchyma was examined under the microscope. Parenchymal lesions were defined as thickening of interalveolar septa due to oedematous swelling, inflammatory cells, or fibrosis associated with hyperplastic epithelial cells.
STATISTICAL ANALYSIS OF DATA
All data were expressed on a per total lung basis, which avoids the artefactual lowering of the values in treated animals due to the presence of proteins of extrapulmonary origin.31 All values are reported as mean (SE). The data were compared within the four groups using two way analysis of variance (SIGMASTAT) and the Student-Newman-Keuls method. A p value of less than 0.05 was considered significant.
TYPE II TGF-β SOLUBLE RECEPTOR (TR) PRODUCTION
The TR was generated from a recombinant rabbit TGFβR:Fc fusion gene comprised of the extracellular domain of the rabbit type II TGF-β receptor fused to the Fc portion of human IgG1 (fig1). The purified dimeric form of the TR was used in the present study.
BIOLOGICAL ACTIVITY OF THE TYPE II TGF-β SOLUBLE RECEPTOR
The biological activity of the TR was determined by a mink lung epithelial cell proliferation assay. When cells were allowed to proliferate in media alone, the amount of [3H]thymidine incorporated was measured as 188 745 counts per minute (cpm). When TGF-β1 was included in the media, proliferation was inhibited and the amount of [3H]thymidine incorporated was measured as 49 088 cpm. As shown in fig 2, TGFβR:Fc relieved 50% (IC50) of TGF-β1 mediated inhibition of proliferation at a concentration of 2 nM. The control did not block the inhibitory effect of TGF-β1 at any of the concentrations tested.
ANIMAL BODY WEIGHT
The average starting body weight of the hamsters used in the study was 125 g and was similar in the four experimental groups. The hamsters in the SA + PBS and SA + TR groups gained an average of about 7 g per animal while the animals in the BL + PBS and BL + TR groups that received intratracheal BL had lost about 2 g by the end of the experiment. There were no deaths in any of the treatment groups. Treatment with TR did not cause any apparent toxicity or changes in body weight compared with the respective PBS treated controls.
LUNG HYDROXYPROLINE CONTENT
Lung hydroxyproline, the index of lung collagen level, was determined for the four groups of hamsters and the results are presented in fig 3. The intratracheal instillation of BL significantly increased the lung hydroxyproline level in the BL + PBS group to 195% of the SA + PBS control group. The BL induced increase in the lung hydroxyproline level in the BL + TR group was decreased significantly (p<0.05) by 33% by the treatment of TR compared with the BL + PBS group. However, the lung hydroxyproline level in the BL + TR group was still significantly higher than that in the two control groups (SA + PBS and SA + TR). Treatment with TR alone had no significant effect on lung collagen level when compared with the PBS control in the saline instilled hamsters (SA + TR vs SA + PBS groups).
PROLYL HYDROXYLASE ACTIVITY
The prolyl hydroxylase activities in the hamster lungs of the four groups are shown in fig 4. BL alone significantly increased the lung prolyl hydroxylase activity in the BL + PBS group to 167% of the SA + PBS control group. TR significantly decreased the prolyl hydroxylase activity increased by the BL treatment in the BL + TR group. However, the prolyl hydroxylase activity in the BL + TR group was still significantly higher than that in the two control (SA + PBS and SA + TR) groups. Treatment with TR had no significant effect on the prolyl hydroxylase activity in the saline instilled lungs since there was no significant difference in the activity of this enzyme between the two control groups (SA + PBS and SA + TR).
TOTAL AND DIFFERENTIAL BAL FLUID CELL COUNTS
The total and differential cell numbers in the BAL fluid of the four groups at 20 days after intratracheal instillation of saline or BL are summarised in table 1. BL treatment increased the total cell counts in the BAL fluid from animals in the BL + PBS and BL + TR groups compared with the saline control groups (SA + PBS and SA + TR). TR had no effect on the saline instilled hamster lungs since there was no significant difference in the cell counts between the two control (SA + PBS and SA + TR) groups. Interestingly, treatment with TR further increased the number of total cells in the BL + TR group compared with the BL + PBS group. Intratracheal instillation of BL, with or without TR, caused increases in the BAL fluid numbers of macrophages, neutrophils, and lymphocytes in the BL + PBS and BL + TR groups. Furthermore, the numbers of neutrophils and lymphocytes in the BL + TR group were even higher than those of the BL + PBS group.
PROTEIN CONTENT IN THE BAL FLUID
The protein content of the BAL fluid supernatant for the four groups is shown in fig 5. Intratracheal instillation of BL significantly increased the BAL fluid protein in both the BL + PBS and BL + TR groups compared with the SA + PBS and SA + TR groups. However, treatment with TR in the BL + TR group did not have any significant effect on the BAL fluid supernatant protein compared with the BL + PBS group.
Histological examination of the lungs revealed normal pulmonary parenchymal tissue in the SA + PBS and SA + TR groups (fig 6A and B). However, as shown in fig 6C, the BL-treated hamster lungs from the BL + PBS group showed a patchy alveolitis and multifocal interstitial fibrosis containing an accumulation of extracellular fibres. The lungs of hamsters in this group had thickened interalveolar septa and inflammatory cells in adjacent air spaces. Compared with the BL + PBS group, lungs from the BL + TR group had fewer fibrotic lesions, although some lobes showed a moderate degree of mononuclear cell alveolitis and slight degree of interstitial fibrosis (fig 6D).
TGF-β has been singled out as one of the most important mediators in collagen synthesis both in vitro and in vivo.7 8 Evidence has accumulated that an increase in TGF-β production is accompanied by, and probably contributes to, the excess collagen accumulation in animal lungs following treatment with BL.13-15 Thus, one of the logical therapeutic strategies would be to prevent the TGF-β production and/or to block the biological activity of this cytokine in response to BL treatment. We chose to antagonise the TGF-β effect by administering the TGF-β soluble receptor which binds to TGF-β with high affinity without signalling, thus effectively abolishing the biological effect of TGF-β. We have shown that treatment with the recombinant TGF-β soluble receptor significantly reduced the BL induced increase in accumulation of lung collagen, as indicated by the reduced hydroxyproline level and fibrotic lesions in the BL + TR group.
An excess accumulation of collagen in the lung is the hallmark of pulmonary fibrosis. Although the mechanisms of increased collagen production in the fibrotic lungs are not entirely clear, various cytokines released as the result of the inflammatory process contribute to the fibrogenesis. Evidence has accumulated that TGF-β plays a crucial role in the extracellular matrix production. Firstly, TGF-β can act on fibroblasts to induce chemotaxis, proliferation, and induction of the synthesis and release of the matrix proteins.32 Secondly, matrix breakdown is prevented by the induction of protease inhibitors by TGF-β such as plasminogen activator inhibitor 1 and tissue inhibitor of metalloproteinase.33 Increased TGF-β mRNA and protein has been associated with the scarring of skin and fibrotic diseases such as glomerulonephritis and pulmonary fibrosis.34-39Studies of human diseases and animal models have recently provided evidence for an involvement of TGF-β1 in the pathogenesis of liver, kidney and lung diseases34 40 and chronic inflammatory disorders such as cirrhosis, glomerulonephritis,38 and pulmonary fibrosis.41 Overexpression of TGF-β1 in pancreatic β cells,42 the livers of transgenic mice,43 or after transfer of TGF-β1 cDNA to rat lung44 resulted in massive fibrosis of the targeted organs. Thus, by inhibiting the effect of TGF-β, the net amount of collagen accumulated can be reduced. However, it is possible that the inhibitory effect of TR on lung prolyl hydroxylase activity might also be related to the reduction of BL induced lung collagen accumulation, since a decreased activity of this enzyme parallelled a reduction in the accumulation of lung collagen content. Increases in the prolyl hydroxylase activity in various animal models of lung fibrosis, including BL-rodent, usually precedes the accumulation of collagen in the lung.45 The enzyme catalysed hydroxylation of proline is an important post-translational event in the processing of highly cross linked mature collagen fibres.46 Inhibition of prolyl hydroxylase activity would allow the deposition of a more pliable and soluble form of collagen which is more susceptible to degradation by intracellular collagenases than cross linked mature collagen fibres.
The generation and characterisation of type II TR have recently been reported.47 48 Type II TR was successfully expressed in yeast and bacteria and shown to be a potent inhibitor for TGF-β1 and TGF-β3 but less effective in the neutralisation of TGF-β2.47 Similar to our approach, Komesli et al 48expressed type II TR in mammalian cells as a fusion protein to the Fc region of human immunoglobulin and found that it was able to bind TGF-β1 and TGF-β3 but not TGF-β2. We have shown in the present study that the TR we produced had a strong inhibitory effect on the function of TGF-β1 although it was unlikely to have a significant effect on TGF-β2. Since TGF-β1 appears to be the predominant isoform expressed during experimental pulmonary fibrosis,9 the ability of the soluble receptor to abrogate TGF-β1 could be sufficient to offer a beneficial effect against lung fibrosis. It has recently been reported that direct delivery of the type II TR gene into the target organ can ameliorate experimental glomerulonephritis49 and liver fibrosis50 in rats. These gene therapy studies elegantly demonstrated the effective strategy of targeting TGF-β by its soluble receptor in the fibrotic diseases. However, the approach we used in the present study of giving the soluble receptor protein itself appears to be more practical and feasible in terms of controlling the dose and schedule of the treatment.
Although treatment with TGF-β soluble receptor decreased the BL induced increase in lung hydroxyproline level, it failed to retard the inflammatory process. BL treatment increased infiltration of the inflammatory leucocyte into the airway and increased vascular permeability, as shown by the numbers of inflammatory cells in the BAL fluid and the protein content of the BAL fluid supernatant. Treatment with TR did not offer protection against the BL induced increase in BAL fluid cell numbers and protein level. In fact, the BL treated hamsters that received TR had higher total cell, neutrophil, and lymphocyte counts. The mechanism by which TR further increases the BL induced increase in influx of inflammatory cells into the airway is not clear. TR itself does not appear to be chemotactic to inflammatory cells since there was no difference in the BAL fluid cell count between the SA + PBS and SA + TR groups. It is known that TGF-β is a strong stimulator of collagen synthesis, but its role in the pathophysiological processes varies depending on the condition; TGF-β not only elicits the pro-inflammatory effect but the anti-inflammatory effect as well,51 the latter being demonstrated by severe inflammatory reactions of various organs including the lungs in TGF-β knockout mice.52 Blocking the effect of TGF-β during BL induced inflammation therefore may not necessarily reduce the infiltration of inflammatory cells. It is possible that BL induced TGF-β may have anti-inflammatory properties and its blockage may lead to a continuation of the acute inflammatory response. Cytokine induced neutrophil chemoattractant (CINC), produced by mouse and rat bone marrow derived macrophages in vitro upon stimulation with lipopolysaccharide, interleukin 1β, and tumour necrosis factor α, was found to be significantly suppressed by TGF-β.53 54Since TGF-β is produced late in the acute inflammatory response, it may function as an important cytokine in the resolution of acute inflammation. Further support for this concept is the observation that macrophages that have ingested apoptotic cells in vitro inhibit pro-inflammatory cytokine production through autocrine/paracrine mechanisms in part by secretion of TGF-β.55Nevertheless, it is still possible for TR to inhibit the effect of TGF-β on collagen production even without decreasing the inflammatory cell infiltration. We have showed that reduction of neutrophil sequestration of BL treated lungs by application of nitroglycerin did not offer significant protection against BL induced lung fibrosis.56 Furthermore, repeated influx of neutrophils into the lung by intratracheal instillation of complement 5a failed to produce lung fibrosis.57 Thus, the status of lung inflammatory cells, especially the number of neutrophils, may not be directly related to the collagen level in BL induced lung fibrosis.
The mechanism of reduced collagen accumulation in BL treated hamster lungs by TR is not completely clear, but it appears to reside in the ability of TR to bind to TGF-β and block its biological activity. The effect of TR in the animal appeared to be specific because intratracheal instillation of an equal amount of bovine serum albumin (BSA) did not have any effect on BL induced lung collagen accumulation in hamsters (the hydroxyproline level being 1839 (53) μg/lung in the BL+BSA group compared with 1823 (41) μg/lung in the BL+PBS group). The biochemical and histopathological evidence provided in this study support the beneficial effect of TR in ameliorating BL induced lung fibrosis. It remains to be determined whether any other route of TR administration and/or different dose schedule would also have a similar or better antifibrotic effect in the BL animal model of lung fibrosis. Furthermore, it would be interesting to test whether TR administration offers a beneficial effect in other animal models of fibrotic diseases such as liver fibrosis and glomerulonephritis. To that endeavour, this study provides the first in vivo evidence that TR may have therapeutic potential for the treatment of pulmonary fibrosis.
This work was supported by Biogen Inc, Cambridge, Massachusetts, USA and grant # RO1 HL56262 from the National Heart, Lung and Blood Institute of the National Institutes of Health, Bethesda, Maryland, USA.